Microtrast (Barium Sulfate)

Barium sulfate, the active ingredient in Microtrast, is a contrast media presented as an oral formulation for diagnostic imaging use. It coats the gastrointestinal tract, providing radiopaque contrast that enhances X‑ray and fluoroscopic visualization during barium studies. GNH USA supplies Microtrast as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Microtrast is employed in gastrointestinal imaging procedures that require radiopaque contrast to delineate the lumen and mucosal surface. - Upper gastrointestinal barium study: provides detailed X‑ray images of the esophagus, stomach and duodenum. - Lower gastrointestinal barium enema: outlines the colon and rectum for diagnostic evaluation. - Fluoroscopic contrast studies: enhances real‑time X‑ray visualization of gastrointestinal motility and function.

Adverse reactions to oral barium sulfate are generally related to gastrointestinal irritation and rare hypersensitivity.

Common Side Effects: - Nausea: mild to moderate feeling of sickness after ingestion. - Abdominal cramping: transient discomfort in the stomach or intestines. - Constipation: reduced bowel movements due to the high density of the agent. - Diarrhoea: occasional loose stools following the study. - Taste alteration: temporary metallic or chalky taste in the mouth. - Vomiting: occasional expulsion of the preparation.

Serious or Rare Side Effects: - Aspiration pneumonia: risk if the suspension is inhaled into the lungs. - Allergic reaction: urticaria, rash, or anaphylaxis in sensitised individuals. - Bowel obstruction: worsening of pre‑existing obstruction. - Perforation risk: potential for bowel wall injury in vulnerable patients. - Severe electrolyte imbalance: rare disturbance due to fluid shifts. - Severe dehydration: excessive fluid loss leading to systemic effects.

Before administering Microtrast, clinicians should evaluate patient history and procedural considerations. - Assess for bowel obstruction: avoid use in patients with known or suspected obstruction. - Review recent gastrointestinal surgery: contraindicated if perforation risk is present. - Check allergy history: do not use in individuals with known hypersensitivity to barium sulfate. - Ensure adequate hydration: advise patients to drink sufficient fluids to prevent constipation. - Pregnancy considerations: use only if the diagnostic benefit outweighs potential risk, as safety data are limited. - Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Barium sulfate may interact with other agents that affect gastrointestinal transit or imaging interpretation.

Major Interactions (Avoid): - Potassium iodide preparations: can interfere with radiographic contrast interpretation. - Oral iodine‑based contrast agents: additive radiopacity may compromise image quality. - Antacids containing aluminum or magnesium: may alter the consistency of the barium suspension.

Moderate Interactions (Monitor Closely): - Laxatives: may increase bowel clearance, reducing image adequacy. - Antidiarrheal agents: may delay barium transit and affect study timing. - Proton pump inhibitors or H2 blockers: may modify gastric acidity, influencing coating effectiveness.